featured
-
Unlocking the Mindâs Eye: How Huntingtonâs Disease Changes How We See and Process the World
For many with Huntingtonâs disease, recognising faces, navigating familiar places, or reading can be difficult. Scientists studied how and when HD affects how the brain processes what we seeâcrucial research to improve support for people with HD.
-
Red Light, Green Light: How Huntingtonâs Disease Influences Genetic Traffic Lights
Huntingtonâs disease disrupts genetic "traffic lights," keeping genes green when they should be red. These genetic traffic jams may act to speed brain cell aging and faulty traffic cops fail to stop the chaos. What does this mean for HD?
-
Navigating the Genetic River: How Tiny Variants Could Shift the Course of Huntingtonâs Disease
Hidden twists in the Huntingtonâs disease gene could shift symptoms by over a decade! Scientists have uncovered rare âgenetic damsâ that shape when HD begins – sometimes dramatically
-
Excitement and Anticipation as PTCâs Huntingtonâs Disease Drug Clears a Major Hurdle to Sprint Home
Votoplam, the daily pill from PTC Therapeutics, has met its primary endpoint in the PIVOT-HD clinical trial – it can lower huntingtin protein levels. This latest data update also provides insights into safety, biomarkers, and clinical measures.
-
Whatâs Good for Your Heart is Good for Your Brain: New Study Links Cardiovascular Health to Brain Aging
Heart health has been linked to lower levels of NfL, a key biomarker of brain cell damage in Huntingtonâs disease. This suggests heart-healthy habits – like exercise and diet – may have an effect on protecting the brain & keeping NfL in check.
-
Assembly Line Breakdown: Protein Production Problems in Huntingtonâs Disease
Huntingtonâs disease slows the cellâs protein factory, causing production line jams & toxicity. A faulty blueprint & missing factory assistant worsen errors. Targeting production slowdowns, not just misfolded products, may help fix the assembly line.
-
April 2025: This Month in Huntingtonâs Disease Research
HDBuzz has ramped up to match the accelerating pace of Huntingtonâs disease research. April 2025 brought us insight on somatic expansion, replacing lost brain cells, and clinical trial updates. Read on for the highlight reel from this month!
-
Stopping C-A-G Repeat Expansion In Its Tracks
A new study shows that lowering MSH3, a key DNA repair protein, with antisense oligonucleotide (ASO) therapy can stop CAG repeat expansions in HD patient-derived brain cells. This could be a promising way to slow symptom onset and progression.
-
Ten Golden Rules for Navigating Huntingtonâs Disease Research News
Avoid the hype: HDBuzz has Ten Golden Rules for navigating news stories or press releases about Huntington's disease.
-
Roche provides an update on tominersen: Whatâs next for this huntingtin-lowering drug?
Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this update mean for the HD community and this trial?